Quick Answer
Keros Therapeutics, Inc. reported Stockholders Equity of $303.13 million for the year ending 2025.
- Keros Therapeutics, Inc. showed a decrease of -47.0% in Stockholders Equity from 2024 to 2025.
- This data is from Keros Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$10.36 million | Q2 2019: -$13.19 million | Q3 2019: -$16.72 million | Q1 2020: -$24.87 million | Q2 2020: $141.36 million | Q3 2020: $130.76 million | Q1 2021: $248.37 million | Q2 2021: $235.66 million | Q3 2021: $218.48 million | Q1 2022: $223.49 million | Q2 2022: $211.21 million | Q3 2022: $241.03 million | Q1 2023: $354.98 million | Q2 2023: $326.26 million | Q3 2023: $295.84 million | Q1 2024: $453.95 million | Q2 2024: $420.92 million | Q3 2024: $532.84 million | Q1 2025: $728.87 million | Q2 2025: $706.73 million | Q3 2025: $703.58 million.
- Over the full 8 years of available data (2018 to 2025), Keros Therapeutics, Inc.'s Stockholders Equity has grown by 4,320.1%.
- Historical annual values: Fiscal year 2025: $303.13 million | Fiscal year 2024: $571.55 million | Fiscal year 2023: $332.21 million | Fiscal year 2022: $277.42 million | Fiscal year 2021: $243.17 million | Fiscal year 2020: $261.72 million | Fiscal year 2019: -$19.45 million | Fiscal year 2018: -$7.18 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: